Jupiter Topco LLC Invests $69.40 Million in Medpace Holdings, Inc. $MEDP

Key Points

• Jupiter Topco LLC acquired 130,948 Medpace shares worth approximately $69.4 million, representing about 0.47% of the company. Other institutional investors also initiated positions, and institutions collectively own 77.98% of Medpace.
• Analysts maintain a consensus “Hold” rating with an average price target of $584.18, despite several firms raising targets to as high as $624. Medpace insiders sold approximately $79.4 million in stock during the last quarter.
• Medpace reported strong quarterly results, with EPS of $4.25 beating estimates and revenue rising 17.2% year over year to $707.33 million. The stock opened at $611.57, with a market capitalization of about $17.07 billion.

Jupiter Topco LLC purchased a new stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 130,948 shares of the company's stock, valued at approximately $69,402,000. Jupiter Topco LLC owned approximately 0.47% of Medpace as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently modified their holdings of the company. Hsbc Holdings PLC bought a new position in Medpace in the second quarter worth approximately $518,000. PDT Partners LLC bought a new stake in Medpace during the 2nd quarter valued at $3,366,000. Canada Pension Plan Investment Board bought a new stake in Medpace during the 2nd quarter valued at $27,980,000. Legal & General Group Plc purchased a new stake in shares of Medpace in the 2nd quarter worth $21,855,000. Finally, The Manufacturers Life Insurance Company purchased a new stake in shares of Medpace in the 2nd quarter worth $10,615,000. Hedge funds and other institutional investors own 77.98% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on MEDP. Leerink Partners set a $620.00 price target on Medpace in a research report on Thursday, July 23rd. TD Cowen upped their price objective on shares of Medpace from $419.00 to $492.00 and gave the stock a "hold" rating in a research note on Friday, July 24th. Barclays set a $600.00 price objective on shares of Medpace in a research note on Thursday, July 23rd. Weiss Ratings raised shares of Medpace from a "hold (c+)" rating to a "buy (b-)" rating in a research report on Wednesday, August 12th. Finally, Robert W. Baird raised their target price on shares of Medpace from $547.00 to $624.00 and gave the company a "neutral" rating in a research report on Friday, July 24th. Three investment analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Hold" and a consensus price target of $584.18.

Insider Activity at Medpace

In other news, Director Fred B. Davenport, Jr. sold 7,283 shares of the business's stock in a transaction on Wednesday, August 19th. The shares were sold at an average price of $606.15, for a total transaction of $4,414,590.45. Following the sale, the director directly owned 3,798 shares of the company's stock, valued at $2,302,157.70. The trade was a 65.73% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO August J. Troendle sold 4,000 shares of the stock in a transaction dated Wednesday, August 26th. The shares were sold at an average price of $620.03, for a total value of $2,480,120.00. Following the completion of the transaction, the chief executive officer directly owned 540,544 shares in the company, valued at $335,153,496.32. This represents a 0.73% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 129,963 shares of company stock worth $79,364,624 in the last quarter. 20.50% of the stock is currently owned by company insiders.

Medpace Stock Performance

NASDAQ:MEDP opened at $611.57 on Friday. The company's 50-day simple moving average is $562.52 and its 200-day simple moving average is $493.80. Medpace Holdings, Inc. has a fifty-two week low of $373.00 and a fifty-two week high of $677.90. The stock has a market capitalization of $17.07 billion, a P/E ratio of 35.85, a P/E/G ratio of 2.76 and a beta of 1.15.

Medpace (NASDAQ:MEDP - Get Free Report) last posted its quarterly earnings data on Wednesday, July 22nd. The company reported $4.25 EPS for the quarter, topping the consensus estimate of $3.98 by $0.27. Medpace had a net margin of 17.67% and a return on equity of 110.15%. The firm had revenue of $707.33 million during the quarter, compared to analyst estimates of $689.51 million. During the same quarter in the previous year, the business posted $3.10 EPS. Medpace's revenue was up 17.2% on a year-over-year basis. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. On average, research analysts forecast that Medpace Holdings, Inc. will post 17.54 EPS for the current year.

About Medpace

Medpace Holdings, Inc NASDAQ: MEDP is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace's core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source